Psoriasis and atopic dermatitis or other forms of eczema are amongst the most common inflammatory diseases. Recent therapeutic developments are tailored for either psoriasis or eczema, respectively. They are costly and require a correct diagnosis. However, this is not given currently: there is a substantial overlap of psoriasis and eczema when using standard diagnostic tools.
Over a decade of research, we have now succeeded in developing a two-gene classifier test which efficiently distinguishes psoriasis from all forms of eczema - even in cases where conventional diagnostic methods failed.
Cutaneous T Cell lymphoma (CTCL) is a malignant tumor of the skin. Using conventional methods, CTCL can rarely be differentiated from inflammatory diseases such as eczema in the initial stage. Adjunct techniques such as T cell clonality analysis are of limited advantage. However, correct and early diagnosis is mandatory to enable the affected patients a normal life expectancy. We currently develop a gene expression based molecular test to allow early diagnosis of CTLC and thus a significantly better prognosis.
Malignant melanoma is the most prevalent cause of death among dermatological diseases. In the last decade, targeted therapies have been developed that require companion diagnostics, namely identification of driver mutations. We will expand our portfolio addressing this high medical need.